Alyeska Investment Group’s VolitionRx Ltd VNRX Stock Holding History

Alyeska Investment Group’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-584	Closed	-$44K	–	851
2021 Q1	$44K	Buy	+584	New	+$50.1K	﹤0.01%	711

Other funds holding VNRX

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's VNRX Position: Q2 2021 in Review

Alyeska Investment Group sold out of VolitionRx Ltd (VNRX) in Q2 2021, closing a stake of 584 shares — an estimated $44K sold.

Alyeska Investment Group first reported a position in VNRX in Q1 2021 and held it in 1 quarter. The position peaked at $44K in Q1 2021. 46 funds tracked by Wall St. Rank hold VNRX as of Q2 2021.

Alyeska Investment Group reported no remaining VolitionRx Ltd position as of Q2 2021 after selling out during the quarter.
Alyeska Investment Group sold 584 VolitionRx Ltd shares in Q2 2021, an estimated $44K.
Alyeska Investment Group first reported a position in VolitionRx Ltd in Q1 2021 and held it in 1 quarter.
Alyeska Investment Group's VolitionRx Ltd position peaked at $44K in Q1 2021.
46 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.